A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients

Status:
Terminated

Trial end date:
2012-02-01

Target enrollment:

Participant gender:

This is a proof of concept study, designed to look at the safety and antiviral activity of LCQ908 in hepatitis C infected patients.

Phase 2

Novartis Pharmaceuticals

Antiviral Agents